Kodiak Sciences Inc · NASDAQ:KOD
Kodiak Sciences — Technical Presentation (2025)
8 slides from Kodiak Sciences's technical presentation, 2025
Slide 1: Bispecific trap-antibody inhibiting IL-6 and VEGF (KSI-101): first-time results from Phase 1b APEX Study
Bispecific trap-antibody inhibiting interleukin-6 and vascular endothelial growth factor (KSI-101): first-time results from the Phase 1b APEX Study in patients with macular edema secondary to inflammation (MESI) Charles C. Wykoff, M.D., Ph.D. Deputy Chair of Ophthalmology, Blanton Eye Institute, Hou
Slide 2: What is macular edema secondary to inflammation (MESI)?
What is macular edema secondary to inflammation (MESI)? Common Common Clinical Unifying therapy? Pathophysiology Presentation VEGF Inflammation IL-6 IL-6 BRB disruption Angiogenesis KSI-101 MESI is a heterogenous group of diseases that clinically present with macular edema and visual impairment, whi
Slide 3: Phase 1b APEX study: multiple dose study of KSI-101 in patients with MESI
Phase 1b APEX study: multiple dose study of KSI-101 in patients Enrollment with MESI complete Study Design: Ongoing, Open-label Phase 1b in MESI Baseline Characteristics Weeks 0 4 8 12 16 20 24 KSI-101 2.5 mg KSI-101 5 mg KSI-101 10 mg All KSI-101 (n=13) (n=14) (n=14) (N=41) Subjects with MESI 2.5 m
Slide 4: Meaningful vision gains rapidly achieved as early as Week 4
APEX KSI-101 in MESI – Meaningful vision gains are rapidly achieved as early as Week 4 and ≥half of patients in the top two dose levels achieved a ≥15 letter gain Observed BCVA over time Proportion of ≥15 letter gainers in patients completing Week 12 in patients completing Week 12 80 100 +11.8 2.5 m
Slide 5: A single dose of KSI-101 results in majority of patients achieving dryness
APEX KSI-101 in MESI – A single dose of KSI-101 results in the majority of patients achieving dryness. Over 90% of patients achieve dryness by Week 8 Observed OCT CST over time Proportion of patients Proportion of patients in patients completing Week 12a achieving absence of IRFb achieving absence o
Slide 6: KSI-101 was well-tolerated. Rapid and meaningful responses achieved even after a single dose
APEX KSI-101 in MESI – KSI-101 was well-tolerated. Rapid and meaningful responses were achieved even after a single dose KSI-101 KSI-101 KSI-101 All KSI-101 2.5 mg 5 mg 10 mg (N=41) (n=13) (n=14) (n=14) Summary of AEs in the Study eye, n (%) Day 1 Subjects with ≥1 AEs 1 (7.7)a 2 (14.3) 2 (14.3) 5 (1
Slide 7: DME – Meaningful visual and anatomical gains achieved with KSI-101
APEX KSI-101 in DME – Meaningful visual and anatomical gains were achieved with KSI-101, with additional benefits with continued dosing. KSI-101 was well-tolerated Study Design: Ongoing, Open-label Mean Change in BCVA and OCT CST in DME Phase 1b in treatment-naïve DME All KSI-101 dose levels combine
Slide 8: Conclusions: KSI-101 demonstrated meaningful visual and anatomical improvements in MESI
Conclusions: KSI-101 demonstrated meaningful visual and anatomical improvements in patients with MESI in the APEX Study • MESI: group of diseases with a shared pathophysiology — inflammation & BRB disruption • Treatment with KSI-101 in MESI patients in APEX, preliminary analysis: VEGF ‒ Robust anato